JP2022529016A5 - - Google Patents
Info
- Publication number
- JP2022529016A5 JP2022529016A5 JP2021561677A JP2021561677A JP2022529016A5 JP 2022529016 A5 JP2022529016 A5 JP 2022529016A5 JP 2021561677 A JP2021561677 A JP 2021561677A JP 2021561677 A JP2021561677 A JP 2021561677A JP 2022529016 A5 JP2022529016 A5 JP 2022529016A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- egfr
- tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835354P | 2019-04-17 | 2019-04-17 | |
| US62/835,354 | 2019-04-17 | ||
| PCT/US2020/028547 WO2020214831A1 (en) | 2019-04-17 | 2020-04-16 | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529016A JP2022529016A (ja) | 2022-06-16 |
| JP2022529016A5 true JP2022529016A5 (enExample) | 2023-04-24 |
| JP7822597B2 JP7822597B2 (ja) | 2026-03-03 |
Family
ID=72837840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561677A Active JP7822597B2 (ja) | 2019-04-17 | 2020-04-16 | チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220193074A1 (enExample) |
| EP (1) | EP3955928A4 (enExample) |
| JP (1) | JP7822597B2 (enExample) |
| KR (1) | KR20220003546A (enExample) |
| CN (1) | CN113784718A (enExample) |
| CA (1) | CA3132816A1 (enExample) |
| WO (1) | WO2020214831A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| PH12021552798A1 (en) | 2019-05-14 | 2022-09-19 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| JP2025537128A (ja) * | 2022-11-03 | 2025-11-14 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 非小細胞肺癌の検出及び治療の方法 |
| CN115998743B (zh) * | 2023-01-16 | 2024-05-28 | 威尚（上海）生物医药有限公司 | 喹唑啉类化合物在克服奥希替尼耐药中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017136709A (ru) * | 2015-04-23 | 2019-05-23 | Медиммьюн Лимитед | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
-
2020
- 2020-04-16 CN CN202080032255.XA patent/CN113784718A/zh active Pending
- 2020-04-16 EP EP20790528.2A patent/EP3955928A4/en active Pending
- 2020-04-16 KR KR1020217037153A patent/KR20220003546A/ko active Pending
- 2020-04-16 JP JP2021561677A patent/JP7822597B2/ja active Active
- 2020-04-16 CA CA3132816A patent/CA3132816A1/en active Pending
- 2020-04-16 WO PCT/US2020/028547 patent/WO2020214831A1/en not_active Ceased
- 2020-04-16 US US17/604,689 patent/US20220193074A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529945A5 (enExample) | ||
| JP2022527788A5 (enExample) | ||
| JP2020502059A5 (enExample) | ||
| JP7265985B2 (ja) | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 | |
| Ponti et al. | BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival | |
| US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2021517894A5 (enExample) | ||
| Kodaz et al. | Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer | |
| JP2022071099A5 (enExample) | ||
| JP2019532011A5 (enExample) | ||
| JP2022527499A5 (enExample) | ||
| Hermsen et al. | Translational genomics of sinonasal cancers | |
| JP2021519262A (ja) | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ | |
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| Jeon et al. | Combination of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer | |
| CN103764847B (zh) | 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法 | |
| JP2021519306A5 (enExample) | ||
| JP2022515128A5 (enExample) | ||
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| Chen et al. | Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants | |
| RS67265B1 (sr) | Lečenje kancera koji ima gnaq ili gna11 genetske mutacije sa inhibitorima protein kinaze c | |
| Grellety et al. | A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| US20130005747A1 (en) | Method for selecting a cancer therapy | |
| Nemtsova et al. | Molecular classifications of gastric cancer and their clinical potential |